| http://www.w3.org/ns/prov#value | - We see this growth mainly driven by a 27%-28% increase in trans-catheter aortic valve (TAV) revenues, amid a still-strong demand for TAV implantation in the U.S. However, while U.S. TAV sales should benefit from the new hospital implantation centers and hospitals stocking the new SAPIENs for trans-apical (TA) implantation, 20 centers delayed TA training.
|
